Gary A. Lyons - 01 May 2023 Form 4 Insider Report for Eledon Pharmaceuticals, Inc. (ELDN)

Reporting relationship: Director
Issuer ticker: ELDN
Reported as of: 01 May 2023
Net transaction value: $0
SEC form: 4
Accepted by SEC: 02 May 2023, 18:44:12 UTC
Prior SEC filing: 02 Feb 2023
Next SEC filing: 19 May 2023
Source filing: View source filing
Reporting owner signature: /s/ Gary Lyons

Key filing fact

Gary A. Lyons filed Form 4 for Eledon Pharmaceuticals, Inc. (ELDN) on 02 May 2023.

Key facts

This page summarizes Gary A. Lyons's Form 4 filing for Eledon Pharmaceuticals, Inc. (ELDN).
1 reported transaction and 1 derivative row are listed below.
Accepted by SEC: 02 May 2023, 18:44.

Change

Previous filing in this sequence was filed on 02 Feb 2023.
Current net transaction value: $0.

Research use

This tells you what this filing adds before you inspect full transaction and derivative tables.
You can trace every row back to the original SEC filing document.

Evidence

Filed on Form 4

Ownership activity is grounded in SEC Form 4 disclosures.

View source filing

Reported derivative securities

Options, warrants, convertible securities, or similar derivative positions disclosed in the filing.

ELDN transaction Derivative

Common Stock

Award

Transaction value: $0
Shares: +150,437
Change %
Price: $0.000000
Shares after: 150,437
Date: 01 May 2023
Ownership: Direct
Underlying class: Common Stock
Underlying amount: 150,437
Exercise price: $2.30
Footnotes: F1

^* marks a reported price that did not pass the local price check.

Additional SEC filing notes

Filing notes and footnotes

Explanation of responses 1 footnote

Footnote F1

This option represents a right to purchase up to 150,437 shares of Common Stock, which option vests with respect to 75,219 shares on May 1, 2024 and with respect to 75,218 shares on May 1, 2025.